Seborrheic dermatitis (SD) is a common multifactorial chronic recurrent inflammatory skin disease that occurs in children and adults, characterized by the formation of erythematous-squamous or papulosquamous rashes in areas with a high concentration of sebaceous glands. The pathogenesis of the disease is not fully understood, but it is assumed that it is associated with hypercolonization of the skin by opportunistic Malassezia yeast, a pronounced immune response to an increase in the fungal population, and genetic predisposition. Chronicity of the process and acute relapses have a significant impact on the quality of life of patients. It is possible to treat acute forms of SD and prolong stable remission with the drug zinc pyrithione. In the current retrospective study, the drug was used in 76 patients who were divided into 3 groups taking into account the clinical symptoms of the process. Depending on clinical symptom, patients were prescribed various dosage forms of zinc pyrithione: shampoo, cream, aerosol. The results of the therapy were assessed 2 weeks after the start of using the drug. The data obtained during the study confirm the literature that it is possible to achieve a pronounced improvement in the process and remission already on the 10–14th day.

Keywords: assessment of the patient’s quality of life, zinc pyrithione, seborrheic dermatitis